Lilly Endowment Inc Sells 8,848 Shares of Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the sale, the insider now directly owns 97,299,772 shares in the company, valued at $89,059,454,309.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

• On Monday, July 1st, Lilly Endowment Inc sold 58,749 shares of Eli Lilly and Company stock. The stock was sold at an average price of $915.26, for a total transaction of $53,770,609.74.
• On Friday, June 28th, Lilly Endowment Inc sold 1,441 shares of Eli Lilly and Company stock. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82.
• On Monday, June 24th, Lilly Endowment Inc sold 17,229 shares of Eli Lilly and Company stock. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02.
• On Thursday, June 20th, Lilly Endowment Inc sold 9,671 shares of Eli Lilly and Company stock. The stock was sold at an average price of $902.67, for a total transaction of $8,729,721.57.
• On Monday, June 17th, Lilly Endowment Inc sold 194,978 shares of Eli Lilly and Company stock. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98.
• On Friday, June 14th, Lilly Endowment Inc sold 15,022 shares of Eli Lilly and Company stock. The shares were sold at an average price of $882.47, for a total transaction of $13,256,464.34.
• On Monday, June 10th, Lilly Endowment Inc sold 75,510 shares of Eli Lilly and Company stock. The shares were sold at an average price of $860.78, for a total transaction of $64,997,497.80.
• On Friday, June 7th, Lilly Endowment Inc sold 139,490 shares of Eli Lilly and Company stock. The shares were sold at an average price of $852.29, for a total transaction of $118,885,932.10.
• On Wednesday, June 5th, Lilly Endowment Inc sold 20,383 shares of Eli Lilly and Company stock. The shares were sold at an average price of $836.32, for a total transaction of $17,046,710.56.
• On Monday, June 3rd, Lilly Endowment Inc sold 192,794 shares of Eli Lilly and Company stock. The shares were sold at an average price of $829.77, for a total transaction of $159,974,677.38.

Eli Lilly and Company Price Performance

NYSE LLY opened at $898.10 on Friday. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $918.50. The stock has a market cap of $853.56 billion, a price-to-earnings ratio of 132.27, a PEG ratio of 1.98 and a beta of 0.41. The company’s 50 day moving average is $824.60 and its two-hundred day moving average is $746.69. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the business earned $1.62 EPS. The firm’s revenue was up 26.0% compared to the same quarter last year. As a group, research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Ratings Changes

A number of analysts have recently issued reports on LLY shares. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Argus raised their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,001.00 price target on shares of Eli Lilly and Company in a report on Wednesday. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $812.72.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LLY. EHP Funds Inc. bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $269,000. Legacy Advisors LLC raised its position in shares of Eli Lilly and Company by 14.7% during the third quarter. Legacy Advisors LLC now owns 2,045 shares of the company’s stock valued at $1,098,000 after buying an additional 262 shares during the last quarter. London Co. of Virginia raised its position in shares of Eli Lilly and Company by 9.2% during the third quarter. London Co. of Virginia now owns 25,654 shares of the company’s stock valued at $13,780,000 after buying an additional 2,168 shares during the last quarter. Jackson Wealth Management LLC raised its position in shares of Eli Lilly and Company by 0.7% during the third quarter. Jackson Wealth Management LLC now owns 6,399 shares of the company’s stock valued at $3,437,000 after buying an additional 47 shares during the last quarter. Finally, Seldon Capital LP bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $217,000. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.